IE83642B1 - Veterinary treatment - Google Patents
Veterinary treatmentInfo
- Publication number
- IE83642B1 IE83642B1 IE1991/1398A IE139891A IE83642B1 IE 83642 B1 IE83642 B1 IE 83642B1 IE 1991/1398 A IE1991/1398 A IE 1991/1398A IE 139891 A IE139891 A IE 139891A IE 83642 B1 IE83642 B1 IE 83642B1
- Authority
- IE
- Ireland
- Prior art keywords
- amoxycillin
- treatment
- clavulanic acid
- veterinarily acceptable
- derivative
- Prior art date
Links
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims abstract description 18
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims abstract description 18
- 229960003022 amoxicillin Drugs 0.000 claims abstract description 12
- 229960003324 Clavulanic Acid Drugs 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 12
- 241000282887 Suidae Species 0.000 claims description 10
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 201000001178 bacterial pneumonia Diseases 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 150000004684 trihydrates Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 abstract description 6
- 230000000844 anti-bacterial Effects 0.000 abstract description 3
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 2
- 229940006939 Clavamox Drugs 0.000 abstract description 2
- 208000004232 Enteritis Diseases 0.000 abstract description 2
- 241000282326 Felis catus Species 0.000 abstract description 2
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 abstract description 2
- 230000037396 body weight Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000606750 Actinobacillus Species 0.000 description 2
- 206010060945 Bacterial infection Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 1
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229960000625 Oxytetracycline Drugs 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229940056360 Penicillin G Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OFPTZWGZSRJCOT-MSPNRCMCSA-M potassium;2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-d Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O OFPTZWGZSRJCOT-MSPNRCMCSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
abstract e describes Synulox", an oral bolus containing amoxycillin and clavulanic acid which may be used for the treatment of enteritis and navel ill in calves. Unlisted Drugs, vol. 38, no. 6, June 1986 mentions Clavamox“, a veterinary tablet containing amoxycillin trihydrate and potassium clavulanate, which is an antibacterial for dogs and cats.
Description
PATENTS ACT, 1992
1398/91
VETERINARY TREATMENT
PFIZER INC.
Veterinam Treatment
This invention relates to a method for the treatment of bacterial infections in
pigs, particularly those infections associated with farrowing fever and bacterial
pneumonia.
GB-B-2 005 538 describes a dry pharmaceutical composition, which comprises
20mg to 1500mg of amoxycillin trihydrate, 20mg to 500mg of potassium
clavulanate and a pharmaceutically acceptable carrier, with the proviso that the
weight ratio of amoxycillin trihydrate to potassium clavulanate is from 6:1 to
1:1.
Unlisted Drugs, vol. 37, no. 1, January 1985, page 13, abstract e describes
Synulox", an oral bolus containing amoxycillin and clavulanic acid which may
be used for the treatment of enteritis and navel ill in calves.
Unlisted Drugs, vol. 38, no. 6, June 1986 mentions Clavamox“, a veterinary
tablet containing amoxycillin trihydrate and potassium clavulanate, which is an
antibacterial for dogs and cats.
EP-A-0010904 discloses intramammary compositions containing amoxycillin, a
salt of clavulanic acid and molecular sieve powder. The compositions are
administered directly into the mammary gland.
According to the present invention there is provided the use of a formulation
comprising an effective amount of amoxycillin or a veterinarily acceptable
derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof,
and a veterinarily acceptable carrier in the manufacture of a medicament for
use by intramuscular injection in the treatment of farrowing fever and bacterial
pneumonia in pigs.
The formulation has notable bactericidal activity against the bacteria associated
with the diseases farrowing fever and bacterial pneumonia in particular
Actinobacillus gleuropneumoniae.
Suitably the clavulanic acid used in the formulation is in the form of
a veterinarily acceptable salt such as potassium clavulanate.
Suitably the amoxycillin used in the formulation is in the form of the
trihydrate or a veterinarily acceptable ester or salt of amoxycillin
such as the sodium salt.
The preferred weight ratio of amoxycillin or derivative to clavulanic
acid or derivative is from 6:1 to 1:1.
Advantageously, a liquid formulation of the invention comprises
36mg/ml clavulanic acid (as potassium clavulanatel and 140mg/ml
amoxycillin las amoxycillin trihydrate).
Preferred veterinarily acceptable carriers include for example
veterinarily acceptable oils such as mineral oils or fractionated
coconut oil such as Miglyol 840.
The formulation is administered to the animal by intramuscular
injection.
The formulation is typically prepared as an off-white suspension and
is presented as a ‘Ready-to-Use’ form, that is the formulation is
prepared and packed in a suitable container, wherein it is ready for
administration to the animal in need thereof.
The dosage rate will vary according to the size of the animal. A
suitable dosage rate is generally between 2 and 25mg/kg
bodyweight of the animal, for example about 8.75mg/kg.
Typically more than a single dose of the formulation will
be required for the treatment of the bacterial infections,
suitably one dose per day for 3 to 5 days is required. In
cases of severe infections prolonged treatment may be
required
Veterinary formulations for use in the present invention may
be prepared by mixing the ingredients thereof in the
required proportions;
The formulation is then packaged into an appropriate
container ready for administration.
The following Example illustrates the invention.
Formulation g/100ml
amoxycillin trihydrate 14.0
potassium clavulanate 3.6
phenol 0.5
Miglyol 840 to 100ml
Clinical data
CASE STUDY 1
Naturally-occuring cases of farrowing fever in pigs were
diagnosed on clinical grounds, then treated on an
alternating basis with either Synu1ox* or a control drug.
The control drug was a penicillin G/streptomycin mixture.
Treatment was administered once daily for a minimum of 3
days. Synulox* was given at a dose rate of lml per 20kg of
body weight.
The clinical response to treatment was scored on a
pre-defined scale:
CR5 1 = excellent
CR5 2 = food
CR5 3 = fair
CR5 4 = poor
(CRS = clinical response score)
From the results which are summarised in FIG 1, it can be
seen that Synulox* has good efficacy in the treatment of
farrowing fever in pigs.
CASE STUDY 2
A total of 229 pigs with pneumonia caused by Actinobacillus
(Haemophilus) pleuropneumonia were involved in this study.
pigs were treated with Synu1ox* and 73 were treated with
a control drug, oxytetracycline (lml/kg body weight
administered intramuscularly). Synulox* was injected
intramuscularly at a dose rate of lml/20kg body weight.
Treatment was continued daily until clinical signs of cough,
dyspnoea, anorexia and depression were remitted and clinical
responses were stored on the basis of the number of
treatments required to achieve remissision. Clinical
response was scored as follows:
CR5 1 = excellent
CR5 2 = good
CR8 3 = fair
CR5 4 = poor
The clinical response scores are summarised in FIG 2,
wherein it was shown that of the total of 156 pigs treated
with Synu1ox* 48.1% showed an "excellent” response, 31.4%
had a ”good” response, 18.6% ”fair" and only 1.9%
"poor" against 35.6% of pigs treated with the control
showing an "excellent” response 32.9%, "good”, 31.5%
”fair" and 0% ”poor”. It was therefore concluded that
Synulox* has good efficacy in the treatment of bacterial
pneumonia in pigs.
* Synulox is a Trademark of Beecham Group p.l.c.
Synulox is an oily suspension contining 35mg/ml clavulanic
acid (K salt) and 140mg/ml amoxycillin (trihydrate).
Claims (5)
1. Use of a formulation comprising an effective amount of amoxycillin or a veterinarily acceptable derivative thereof, clavulanic acid or a veterinarily acceptable derivative thereof, and a veterinarily acceptable carrier, in the manufacture of a medicament for use by intramuscular injection in the treatment of farrowing fever or bacterial pneumonia in pigs.
2. The use according to claim 1, wherein the clavulanic acid is used in the form of potassium clavulanate.
3. The use according to claim 1 or 2, wherein the amoxycillin is used in the form of the trihydrate or the sodium salt.
4. The use according to claim 1, 2, or 3, wherein the weight ratio of amoxycillin or derivative to clavulanic acid or derivative is from 6:1 to 1:1.
5. The use according to claim 1, 2, 3, or 4, wherein the veterinarily acceptable carrier is an oil suitable for injection. F. R. KELLY & CO., AGENTS FOR THE APPLICANTS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBUNITEDKINGDOM26/04/19909009446.7 | |||
| GB909009446A GB9009446D0 (en) | 1990-04-26 | 1990-04-26 | Veterinary composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE83642B1 true IE83642B1 (en) | |
| IE911398A1 IE911398A1 (en) | 1991-11-06 |
Family
ID=10675074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE139891A IE911398A1 (en) | 1990-04-26 | 1991-04-25 | Veterinary treatment |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0607122B1 (en) |
| JP (1) | JPH05506237A (en) |
| KR (1) | KR100203704B1 (en) |
| AT (1) | ATE203160T1 (en) |
| AU (1) | AU648792B2 (en) |
| CA (1) | CA2081348C (en) |
| DE (1) | DE69132663T2 (en) |
| DK (1) | DK0607122T3 (en) |
| ES (1) | ES2157888T3 (en) |
| GB (1) | GB9009446D0 (en) |
| GR (1) | GR3036905T3 (en) |
| IE (1) | IE911398A1 (en) |
| NZ (1) | NZ237931A (en) |
| WO (1) | WO1991016050A1 (en) |
| ZA (1) | ZA913073B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9007143D0 (en) * | 1990-03-30 | 1990-05-30 | Beecham Group Plc | Veterinary composition |
| US5324840A (en) * | 1992-06-11 | 1994-06-28 | Allergan, Inc. | Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1508977A (en) * | 1924-01-19 | 1924-09-16 | John Armstrong Hume | Advertising device |
| IE41109B1 (en) * | 1974-04-20 | 1979-10-24 | Beecham Group Ltd | Novel -lactam antibiotic from streptomyces clavuligerus |
| US4529720A (en) * | 1974-04-20 | 1985-07-16 | Beecham Group, P.L.C. | Antibiotic from Streptomyces clavulicerus |
| JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | K-clavulanate/tri hydrate formulations |
| IL58461A0 (en) * | 1978-10-27 | 1980-01-31 | Beecham Group Ltd | Intramammary compositions comprising a clavulanic acid salt |
| GB9007143D0 (en) * | 1990-03-30 | 1990-05-30 | Beecham Group Plc | Veterinary composition |
-
1990
- 1990-04-26 GB GB909009446A patent/GB9009446D0/en active Pending
-
1991
- 1991-04-22 ES ES91908740T patent/ES2157888T3/en not_active Expired - Lifetime
- 1991-04-22 KR KR1019920702637A patent/KR100203704B1/en not_active IP Right Cessation
- 1991-04-22 DK DK91908740T patent/DK0607122T3/en active
- 1991-04-22 JP JP91508210A patent/JPH05506237A/en active Pending
- 1991-04-22 EP EP91908740A patent/EP0607122B1/en not_active Revoked
- 1991-04-22 AU AU77581/91A patent/AU648792B2/en not_active Expired
- 1991-04-22 CA CA002081348A patent/CA2081348C/en not_active Expired - Lifetime
- 1991-04-22 DE DE69132663T patent/DE69132663T2/en not_active Revoked
- 1991-04-22 AT AT91908740T patent/ATE203160T1/en not_active IP Right Cessation
- 1991-04-22 WO PCT/GB1991/000635 patent/WO1991016050A1/en not_active Application Discontinuation
- 1991-04-24 ZA ZA913073A patent/ZA913073B/en unknown
- 1991-04-24 NZ NZ237931A patent/NZ237931A/en unknown
- 1991-04-25 IE IE139891A patent/IE911398A1/en not_active IP Right Cessation
-
2001
- 2001-10-16 GR GR20010401775T patent/GR3036905T3/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ197530A (en) | Pharmaceutical compositions comprising 2-imidazolines | |
| US6479473B1 (en) | Long-acting antimicrobials | |
| KR102419769B1 (en) | drug composition | |
| EP0607122B1 (en) | Veterinary treatment | |
| GB2087236A (en) | Pharmaceutical preparations containing a 6 beta -halopenicillanic acid | |
| IE83642B1 (en) | Veterinary treatment | |
| US5643902A (en) | Veterinary treatment | |
| EP1604660B1 (en) | Medicinal composition for treating infection with drug-resistant staphylococcus aureus | |
| SA97180188B1 (en) | Composition and method of preparation of carbapenem as an antibiotic | |
| US4145429A (en) | Oral veterinary preparations | |
| JPS59205321A (en) | Anthelmintic synergistical novel composition | |
| CA2079328C (en) | Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof | |
| AU606330B2 (en) | Sulphonamide /diaminopyrimidine compositions for the treatment of microbial infections | |
| CN107789355B (en) | Compound pharmaceutical composition containing piperacillin and application thereof | |
| RU2103997C1 (en) | Medicinal agent for treatment of animal disease of bacterial etiology, method of treatment of animal gastroenteric disease of bacterial etiology and methods of treatment of gynecological disease of bacterial etiology in animals | |
| AU621459B2 (en) | Compositions comprising baquiloprim and sulphadimethoxine | |
| RU2108783C1 (en) | Antibacterial preparation for agriculture animal treatment | |
| KR960015952B1 (en) | Antidiarrheial therapeutic agents for animal and the pharmaceutical compositions comprising them | |
| JPH11501904A (en) | Pharmaceutical formulation comprising clavulanic acid salt, vancomycin and one or more beta-lactam antibiotics | |
| IE57352B1 (en) | Composition having improved pharmaceutical activity and use of it for veterinary purposes | |
| JPS6143116A (en) | Method and agent for remedy of bacteriosis |